0000899243-15-010542.txt : 20151231 0000899243-15-010542.hdr.sgml : 20151231 20151231160521 ACCESSION NUMBER: 0000899243-15-010542 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20151230 FILED AS OF DATE: 20151231 DATE AS OF CHANGE: 20151231 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Carbylan Therapeutics, Inc. CENTRAL INDEX KEY: 0001348911 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 200915291 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3181 PORTER DRIVE CITY: PALO ALTO STATE: CA ZIP: 94304 BUSINESS PHONE: 650-855-6777 MAIL ADDRESS: STREET 1: 3181 PORTER DRIVE CITY: PALO ALTO STATE: CA ZIP: 94304 FORMER COMPANY: FORMER CONFORMED NAME: Carbylan Biosurgery, Inc DATE OF NAME CHANGE: 20130102 FORMER COMPANY: FORMER CONFORMED NAME: Carbylan Biosurgery Inc DATE OF NAME CHANGE: 20060105 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Renzi David CENTRAL INDEX KEY: 0001631294 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36830 FILM NUMBER: 151315956 MAIL ADDRESS: STREET 1: C/O CARBYLAN THERAPEUTICS, INC. STREET 2: 3181 PORTER DRIVE CITY: PALO ALTO STATE: CA ZIP: 94304 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2015-12-30 0 0001348911 Carbylan Therapeutics, Inc. CBYL 0001631294 Renzi David C/O CARBYLAN THERAPEUTICS, INC. 3181 PORTER DRIVE PALO ALTO CA 94304 1 1 0 0 President & CEO Common Stock 2015-12-30 4 M 0 10000 0.56 A 10000 D Common Stock 2015-12-30 4 S 0 10000 3.70 D 0 D Stock Option (Right to Buy) 0.56 2015-12-30 4 M 0 10000 0.00 D 2023-06-06 Common Stock 10000 515825 D The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Represents the weighted-average price at which shares were sold within a range between $3.65 and $3.725, inclusive. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The option for 525,825 shares of common stock was granted on 6/6/2013. 1/4 of the option grant was fully vested and exercisable on 6/6/2014, and 1/48 of the option grant vests and becomes exercisable each month thereafter. /s/ David J. Saul, Attorney-in-fact 2015-12-31